Steven Annen Buys 5,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) SVP Steven Annen bought 5,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the transaction, the senior vice president owned 136,490 shares of the company’s stock, valued at $648,327.50. This represents a 3.80% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

FocalTherics Price Performance

FOCL stock opened at $4.76 on Monday. FocalTherics has a 52-week low of $1.30 and a 52-week high of $6.40. The company’s 50 day moving average price is $5.39. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The firm has a market capitalization of $178.40 million, a price-to-earnings ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The firm had revenue of $13.20 million during the quarter. Sell-side analysts predict that FocalTherics will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on FOCL. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.75.

Institutional Investors Weigh In On FocalTherics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rock Springs Capital Management LP boosted its stake in shares of FocalTherics by 7.1% during the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after buying an additional 91,500 shares during the period. Lido Advisors LLC acquired a new position in shares of FocalTherics in the first quarter worth $40,000. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics in the first quarter worth $38,000. Flax Pond Capital LLC purchased a new stake in shares of FocalTherics during the fourth quarter worth $2,623,000. Finally, Kovack Advisors Inc. purchased a new stake in shares of FocalTherics during the fourth quarter worth $53,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.